SCHEMBL3584740

SCHEMBL3584740

COc1ccc(C=C2CCN(C)CC2)c([N+](=O)[O-])c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
MAPK1 P28482 1/20 0.45
DRD2 P14416 3/20 0.43
DRD1 P21728 3/20 0.43
DRD5 P21918 3/20 0.43
DRD3 P35462 3/20 0.43
SIRT6 Q8N6T7 1/20 0.42
MAPT P10636 3/20 0.42
RECQL P46063 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PTGS2 P35354 1/20 0.41
ACHE P22303 1/20 0.41
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DRD4 P21917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3582319 0.87 ALDH1A1 (0.46) ALDH1A1MAPK1MAPTRECQLCYP3A4
SCHEMBL3582128 0.85 MAPT (0.47) ALDH1A1MAPK1MAPTRECQLHTT
SCHEMBL3579559 0.85 ALDH1A1 (0.47) ALDH1A1MAPK1MAPTRECQLHTT
SCHEMBL3586175 0.85 ALDH1A1 (0.45) ALDH1A1MAPK1MAPTRECQLCYP3A4
SCHEMBL3581134 0.83 ALDH1A1 (0.43) ALDH1A1MAPK1MAPTCYP3A4SMN1; SMN2
SCHEMBL3580185 0.83 ALDH1A1 (0.43) ALDH1A1MAPK1MAPTCYP3A4SMN1; SMN2
SCHEMBL3577423 0.82 MAPT (0.46) ALDH1A1MAPK1MAPTRECQLHTT
SCHEMBL3584459 0.80 ALDH1A1 (0.43) ALDH1A1MAPK1MAPTRECQLSMN1; SMN2
SCHEMBL3576300 0.80 ALDH1A1 (0.44) ALDH1A1MAPK1MAPTRECQLSMN1; SMN2
SCHEMBL3576294 0.80 ALDH1A1 (0.44) ALDH1A1MAPK1MAPTRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
EP-2118076-A1 QUINOXALINE COMPOUNDS AND USE THEREOF Merck Serono S.A. (CH) 2009-11-18 EP disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 ALDH1A1 577/4885MAPK1 2681/4885DRD2 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.